Editorial Filippou Dimitrios Ass. Professor, Medical School, National and Kapodestrian University of Athens Doi: 10.5281/zenodo.18039189. Surgical site infections (SSIs) pose a significant challenge for modern healthcare systems globally. Even with substantial advancements in surgical methods, antimicrobial treatments, and infection control measures, SSIs maintain a distressing toll on patients, healthcare facilities, and society as a whole. Recent statistics showing a 2% rise in standardized infection ratios across various surgical procedures, alongside a 3% increase in infections linked to Surgical Care Improvement Project protocols, indicate a troubling regression in progress that requires urgent action from policymakers, healthcare providers, and administrators. The severity of the SSI dilemma is profound. Current data estimates suggest around 110,800 SSIs occur each year in the U.S. due to inpatient surgeries. These infections represent 20% of all healthcare-associated infections, marking them as the most prevalent and expensive type of nosocomial complication. The financial burden is staggering, with yearly costs surpassing $3.3 billion and each infected patient incurring over $20,000 in additional expenses. Furthermore, SSIs extend hospital stays by an average of 9.7 days, resulting in significant repercussions for healthcare capacity and resource distribution. The mortality rate associated with surgical site infections is one of the most alarming aspects of this crisis. Patients suffering from SSIs experience a mortality risk that is 2 to 11 times higher, with roughly 75% of deaths linked to the infection itself. In 2002 alone, more than 8,200 deaths in the U.S. were directly caused by surgical site infections, which constituted 8% of all nosocomial infection-related fatalities. Such figures highlight that SSIs are not merely complications of care but serious health threats necessitating prompt preventive strategies. The epidemiological landscape of surgical site infections exhibits considerable variation across surgical specialties and patient demographics. Incidence rates can be as low as 1% in clean, uncomplicated surgeries and soar to 30% in contaminated or emergency procedures. Orthopedic surgeries, particularly joint arthroplasties, carry a notably high risk of SSIs, leading to devastating outcomes such as implant failure and prolonged disability. Cardiac surgical patients face sternal wound infections that compromise both cardiac and respiratory functions. Colorectal surgeries, due to the natural bacterial contamination of the gastrointestinal tract, consistently show elevated infection rates, necessitating specialized preventive measures. The global differences in SSI rates raise additional issues. Low- and middle-income nations encounter notably higher infection rates, with pediatric SSI rates hitting 5.4% in India, 6.7% in Brazil, and 18.7% in Mexico. These alarming figures illustrate systemic issues such as inadequate monitoring systems, limited access to preventive antibiotics, shortages of qualified personnel, and basic sanitation challenges. The economic effects in these regions can be even more severe than in wealthier countries, as families often face catastrophic out-of-pocket costs for extended treatments and multiple surgeries. The origins of surgical site infections stem from complex interactions between microbial contamination, host immune defenses, and surgical techniques. Staphylococcus aureus, including its methicillin-resistant variants (MRSA), remains the leading pathogen, responsible for nearly 50% of SSIs following hip and knee arthroplasties. The organism’s ability to produce biofilms on implanted devices creates particularly tough treatment challenges, often requiring the removal of devices and prolonged antimicrobial therapy. Gram-negative bacteria like Escherichia coli and Pseudomonas aeruginosa also play significant roles in infections following gastrointestinal and genitourinary surgeries. Recognizing that around half of all surgical site infections may be preventable through evidence-based strategies provides both motivation and urgency for action. The Centers for Disease Control and Prevention, along with global organizations like the World Health Organization and the National Institute for Health and Care Excellence, have formulated comprehensive guidelines that address preoperative, intraoperative, and postoperative practices. Nonetheless, adherence to these guidelines remains inconsistent, with significant gaps between recommended practices and everyday clinical care. Preoperative optimization is a vital yet frequently underutilized avenue for SSI prevention. Targets for interventions include modifiable patient-specific risk factors such as glycemic control, nutritional status, smoking cessation, and nasal decolonization. Diabetic patients with inadequate glycemic control show significantly heightened infection rates, yet protocols for managing perioperative glucose are often applied inconsistently. Smoking cessation initiatives, when implemented at least 30 days before elective surgery, can lead to marked reductions in SSI risk, although surgical schedules may limit adequate preparation time. Decolonization of Staphylococcus aureus has proven to be an effective preventive measure, especially for high-risk orthopedic and cardiac procedures. Universal screening combined with a 5-day regimen of nasal mupirocin and chlorhexidine body washes has been shown to reduce SSI rates by approximately 30-40%. Post-discharge decolonization protocols that extend this protection during the critical recovery phase further enhance outcomes. However, effective implementation requires substantial investment in infrastructure for screening, coordination, and patient education—priorities that many institutions have not yet adopted. The timing and selection of antimicrobial prophylaxis greatly influence SSI risk. Administering prophylactic antibiotics within 60 minutes of incision ensures adequate tissue concentrations during the key period of bacterial exposure. The choice between β-lactam and non-β-lactam agents has meaningful implications—recent large cohort studies reveal a 1.8-fold increase in SSI odds linked to non-β-lactam prophylaxis. This crucial finding underscores the need for careful assessment of reported β-lactam allergies, as inappropriate avoidance of first-line agents can significantly elevate infection risks. Intraoperative contributors to the development of surgical site infections (SSIs) include surgical techniques, environmental controls, and physiological management. Ensuring positive pressure ventilation with a minimum of 15 air changes per hour in the operating room significantly reduces airborne contaminants. Limiting traffic within the operating room, guaranteeing proper sterilization of instruments, and maintaining normal body temperature are all key elements in preventing infections. There is a direct relationship between surgery duration and SSI risk, highlighting the necessity for efficiency while maintaining precise technical performance. Wound care in the early postoperative phase has gained notable attention as a modifiable risk element. Although traditional dry gauze dressings continue to be the norm, advanced dressing options, such as hydrocolloids, silver-infused materials, and negative-pressure systems, potentially provide benefits in moisture regulation, bacterial reduction, and optimal wound conditions. Evidence indicates that dressing choice may have a modest effect on SSI rates, with silver-containing dressings particularly showing promise in contaminated surgeries. Strong recommendations advocate for keeping primary dressings undisturbed for 48 hours post-surgery to minimize opportunities for bacterial entry. The introduction of bundled preventive measures has proven highly effective in lowering SSI rates across various surgical populations. Care bundles that incorporate multiple evidence-based practices—such as appropriate antibiotic prophylaxis, chlorhexidine skin prep, using clippers instead of razors for hair removal, managing glycemia, and maintaining normothermia—create synergistic benefits that surpass the impact of individual measures. Meta-analyses of interrupted time series studies reveal significant reductions in SSI rates after implementing these bundles, with sustained effects observed during prolonged follow-up. Surveillance and feedback mechanisms are critical components of successful SSI prevention programs. The CDC’s National Healthcare Safety Network offers standardized definitions and reporting frameworks that facilitate inter-institutional comparisons and benchmarking. Providing surgical teams with regular feedback on SSI rates, categorized by risk factors and types of procedures, fosters performance improvement and identifies outliers in need of targeted intervention. However, rigorous surveillance demands considerable resources, and underreporting remains a significant concern that can obscure the true burden of infections. The rise of antimicrobial resistance poses an increasing challenge to the prevention and treatment of SSIs. Multidrug-resistant pathogens, including MRSA, vancomycin-resistant enterococci, and carbapenem-resistant Enterobacteriaceae, complicate choices for prophylaxis and treatment. The current pipeline for new antimicrobial agents is insufficient, which underscores the necessity for stewardship programs to optimize the use of existing antibiotics. Antibiotic prophylaxis should be confined to the immediate perioperative period, as prolonged use can encourage resistance without significantly lowering SSI rates. Healthcare system factors greatly affect the incidence and outcomes of SSIs. Nurse staffing levels, operating room turnover demands, and resource availability all play a role in infection prevention efforts. The COVID-19 pandemic highlighted the vulnerability of SSI prevention advancements, with numerous institutions reporting increased infection rates amid staffing shortages, supply chain disruptions, and altered clinical priorities. Recovery from pandemic-related challenges mandates renewed commitment to strengthening infection prevention infrastructures and personnel. The financial rationale for investing in SSI prevention is strong. Despite the initial expenses associated with decolonization programs, advanced dressings, and surveillance systems, the costs avoided from extended hospital stays, additional surgeries, and long-term complications result in a favorable return on investment. Cost-effectiveness analyses consistently show that preventive spending leads to significant savings, especially in high-volume surgical settings. However, misaligned financial incentives—where the costs of prevention fall on institutions while the savings mainly benefit payers—pose barriers to implementation that require policy interventions. Future efforts in SSI prevention are likely to involve technological advancements and systems engineering strategies. Emerging technologies, such as antimicrobial-coated sutures, photodynamic disinfection, and bacteriophage therapy, hold promise as complementary measures to current strategies. Applications of artificial intelligence for risk assessment and early detection may facilitate targeted prevention efforts and prompt therapeutic responses. Nonetheless, these innovations necessitate thorough evaluation to ensure they enhance rather than detract from fundamental preventive strategies. The worldwide challenge of surgical site infections demands a coordinated international effort. The World Health Organization’s Global Guidelines for the Prevention of Surgical Site Infection offer a framework relevant to various resource settings, though their implementation must be tailored to local circumstances. Building capacity in low - and middle-income countries, including developing surveillance systems and training programs, is both a moral responsibility and an investment in global health security. In conclusion, surgical site infections are a preventable catastrophe within modern healthcare. The increasing infection rates highlighted in recent surveillance data should alert healthcare systems globally. There is a robust evidence foundation for effective prevention, a compelling economic case for investment, and a clear moral imperative. The challenge ahead is the collective determination to prioritize SSI prevention, allocate adequate resources, and sustain efforts across a range of clinical environments. The benefits, including lives saved, reduced morbidity, and cost savings, will significantly reward these commitments. References 1. Centers for Disease Control and Prevention. Surgical Site Infection Event (SSI) Protocol. NHSN Patient Safety Manual. 2024. Available at: https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf 2. de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg. 2017;104:118-133. 3. Leaper D, Tanner J, Kiernan M. Surveillance of surgical site infection: more accurate definitions and intensive recording needed. J Hosp Infect. 2013;83:83-86. 4. Tanner J, Padley W, Kiernan M, Leaper D, Norrie P, Baggott R. A benchmark too far: findings from a national survey of surgical site infection surveillance. J Hosp Infect. 2013;83:87-91. 5. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection. JAMA Surg. 2017;152:784-791. 6. World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. Geneva: WHO; 2016. 7. National Institute for Health and Care Excellence. Surgical Site Infection: Prevention and Treatment. NICE Guideline NG125. 2019. 8. Carter EB, Temming LA, Fowler S, et al. Evidence-based bundles and cesarean delivery surgical site infections: a systematic review and meta-analysis. Obstet Gynecol. 2017;130:735-746. 9. Monahan M, Jowett S, Pinkney T, et al. Surgical site infection and costs in low- and middle-income countries: a systematic review of economic evaluations. PLoS One. 2020;15(6):e0233158. 10. Ganz RA. The evaluation and treatment of hemorrhoids: a guide for the gastroenterologist. Clin Gastroenterol Hepatol. 2013;11(6):593-603. 11. Centers for Disease Control and Prevention. Environmental Infection Control Guidelines: Air. 2023. Available at: https://www.cdc.gov/infection-control/hcp/environmental-control/air.html 12. Tomsic I, Chaberny IF, Heinze NR, Krauth C, Schock B, von Lengerke T. Perioperative care bundles for the prevention of surgical-site infections: meta-analysis. Br J Surg. 2020;107:1585-1598. 13. Pop-Vicas AE, Abad C, Baubie K, Osman F, Heise C, Safdar N. Colorectal bundles for surgical site infection prevention: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2020;41:805-812. 14. Leaper DJ. Silver dressings: their role in wound management. Int Wound J. 2006;3:282-294. 15. Schweizer ML, Chiang HY, Septimus E, et al. Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. 2015;313(21):2162-2171. 16. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368(24):2255-2265. 17. Bode LGM, Kluytmans JAJW, Wertheim HFL, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362(1):9-17. 18. Schweizer M, Perencevich E, McDanel J, et al. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. 2013;346:f2743. 19. Anderson DJ, Podgorny K, Berrios-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(6):605-627. 20. Zywot A, Lau CSM, Fletcher HS, Paul S. Bundles prevent surgical site infections after colorectal surgery: meta-analysis and systematic review. J Gastrointest Surg. 2017;21:1915-1930